サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1739165

インスリン様成長因子の世界市場

Insulin-like Growth Factors

出版日
ページ情報
英文 270 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.12円
インスリン様成長因子の世界市場
出版日: 2025年06月03日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 270 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

インスリン様成長因子の世界市場は2030年までに3億5,520万米ドルに達する見込み

2024年に2億8,170万米ドルと推定されるインスリン様成長因子の世界市場は、分析期間2024-2030年にCAGR 3.9%で成長し、2030年には3億5,520万米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるメカノ成長因子は、CAGR 4.3%を記録し、分析期間終了時には2億2,250万米ドルに達すると予測されます。ソマトメジンCセグメントの成長率は、分析期間中CAGR 3.0%と推定されます。

米国市場は7,670万米ドルと推定、中国はCAGR7.3%で成長すると予測

米国のインスリン様成長因子市場は、2024年には7,670万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに7,230万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.6%と3.1%と予測されています。欧州では、ドイツがCAGR 2.3%で成長すると予測されています。

世界のインスリン様成長因子市場- 主要動向と促進要因のまとめ

インスリン様成長因子とは何か、なぜ生物医学的に注目されているのか？

主にIGF-1とIGF-2であるインスリン様成長因子（IGFs）は、インスリンと構造的に類似した天然由来のポリペプチドであり、成長、細胞増殖、組織再生において重要な役割を果たしています。IGFは、成長ホルモン（GH）活性のメディエーターとして作用し、幼児期の開発だけでなく、筋肉修復、骨密度維持、臓器再生などの成人の同化過程においても不可欠です。このような生物学的役割のため、IGFは内分泌学、腫瘍学、代謝性疾患、再生医療にわたる研究開発の焦点となっています。

IGFは、その生理的役割にとどまらず、がんの進行、加齢に伴う筋肉の衰え（サルコペニア）、神経変性疾患、糖尿病などの病態への関与についても研究されています。組換えIGF製剤、IGF受容体モジュレーター、およびアナログの治療の可能性は、特に個別化医療と生物製剤が主流になるにつれて、拡大しつつあります。組織再生の促進と異常な細胞増殖への寄与というIGFの二重の役割から、正確な治療標的が必要とされ、医薬品開発、診断、標的デリバリー・システムにおける技術革新の機会が生み出されています。

技術革新はどのようにIGFに基づく治療と診断の開発を形成しているのか？

分子生物学、蛋白質工学、および受容体シグナル伝達分析における科学的進歩は、IGFに基づく治療法の開発を加速しています。組換えIGF-1療法は現在、成長ホルモン分泌不全症（ラロン症候群）、重度の火傷、筋萎縮障害などの症状に対して研究されています。バイオテクノロジー企業は、薬物動態と受容体選択性を改善したIGFアナログを積極的に設計し、治療効果を最大化する一方、標的外影響を最小化しています。これと並行して、IGF結合タンパク質（IGFBP）は、バイオアベイラビリティを調節し、IGF関連薬の安全性プロファイルを高めるために活用されつつあります。

診断の面では、下垂体機能の評価、成長障害の診断、内分泌療法における治療効果のモニタリングにおいて、循環IGF-1レベルの測定が重要性を増しています。さらに、IGF受容体発現プロファイリングは、腫瘍学、特にIGFシグナル伝達が腫瘍増殖と治療抵抗性に関与している乳がん、前立腺がん、大腸がんにおいて、潜在的なバイオマーカーとして浮上しています。バイオアッセイプラットフォームとハイスループットスクリーニング技術の進歩により、IGFとその関連経路のより正確な定量化が可能となり、臨床診断と患者層別化における役割が拡大しています。

IGFベースのソリューションに対する需要を拡大している臨床及び研究領域は？

内分泌学は、特に小児の成長障害とGH欠乏症の治療において、IGF利用の主要な領域であり続けています。しかし、その範囲は他の治療領域にも急速に広がっています。筋骨格系と整形外科医学では、軟骨、腱、骨の治癒と修復を促進するために、組織工学と再生療法プロトコルにIGFが組み込まれています。スポーツ医学もまた、成長しつつある応用分野であり、規制や倫理的な監視の中でではあるが、IGFに基づく治療がアスリートの筋肉再生と回復のために研究されています。

いくつかの腫瘍がIGF受容体の過剰発現を示すか、増殖と生存のためにIGFシグナル伝達に依存していることから、腫瘍学はIGF研究の重要なフロンティアです。このため、抗IGF受容体抗体や低分子阻害剤の開発を促し、標的がん治療においてこれらの経路を破壊しています。神経学と老年医学は新たな関心領域であり、IGFはアルツハイマー病、認知機能低下、加齢に伴う神経変性における神経保護作用について研究されています。細胞ベースの治療、遺伝子編集、再生医療におけるIGFの広範な応用は、将来の生物医学革新におけるIGFの戦略的重要性を強調しています。

インスリン様成長因子市場の成長はいくつかの要因によって牽引されている...

それは、健康および疾病の両方におけるIGFシグナル伝達に関する理解の拡大、およびバイオ医薬品開発プラットフォームの急速な進歩です。内分泌・代謝疾患の有病率の増加は、世界の人口の高齢化と相まって、筋肉の衰え、成長不全、変性疾患に対処する治療薬への需要を煽っています。タンパク質工学と組換えDNA技術における技術的飛躍的進歩により、特異性の高いIGFアナログとモジュレーターの生産が可能になり、治療効果と安全性が向上しています。

これと並行して、臨床診断におけるIGF測定法の統合は、特に成長ホルモン療法モニタリング、腫瘍学バイオマーカープロファイリング、代謝性疾患評価において、より一般的になりつつあります。幹細胞研究と足場設計の革新に支えられた再生医療とIGFに基づく介入の融合は、新たな治療の道を開きつつあります。さらに、老化、認知、免疫調節におけるIGFの役割に関する臨床研究の拡大により、これらの分子は次世代生物学的薬剤パイプラインの重要な標的として位置づけられています。分野横断的な応用、臨床適応の拡大、旺盛な研究開発投資の組み合わせが、インスリン様成長因子市場の長期的な成長を維持すると予想されます。

セグメント

タイプ（メカノグロースファクター、ソマトメジンC、IGF 1）;エンドユース（病院、医療センター）

調査対象企業の例（注目の36社）

  • ABL Bio
  • Biocon Limited
  • Biomed Industries, Inc.
  • Bio-Techne
  • Braasch Biotech LLC
  • Cell Guidance Systems
  • ConjuChem Biotechnologies Inc.
  • Eli Lilly and Company
  • HyTest Ltd.
  • Kriya Therapeutics
  • Novo Nordisk A/S
  • Oak Hill Bio
  • PerkinElmer（Revvity）
  • Repligen Corporation
  • Rivus Pharmaceuticals
  • Sana Biotechnology
  • STEMCELL Technologies
  • Thermo Fisher Scientific
  • Vertex Pharmaceuticals
  • Zymo Research

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP33978

Global Insulin-like Growth Factors Market to Reach US$355.2 Million by 2030

The global market for Insulin-like Growth Factors estimated at US$281.7 Million in the year 2024, is expected to reach US$355.2 Million by 2030, growing at a CAGR of 3.9% over the analysis period 2024-2030. Mechano Growth Factor, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$222.5 Million by the end of the analysis period. Growth in the Somatomedin C segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$76.7 Million While China is Forecast to Grow at 7.3% CAGR

The Insulin-like Growth Factors market in the U.S. is estimated at US$76.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$72.3 Million by the year 2030 trailing a CAGR of 7.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Insulin-like Growth Factors Market - Key Trends & Drivers Summarized

What Are Insulin-like Growth Factors and Why Are They Gaining Biomedical Attention?

Insulin-like Growth Factors (IGFs), primarily IGF-1 and IGF-2, are naturally occurring polypeptides with structural similarity to insulin and play a critical role in growth, cell proliferation, and tissue regeneration. IGFs act as mediators of growth hormone (GH) activity and are essential in early childhood development, as well as in adult anabolic processes such as muscle repair, bone density maintenance, and organ regeneration. Due to these biological roles, IGFs have become a focal point of research and development across endocrinology, oncology, metabolic diseases, and regenerative medicine.

Beyond their physiological roles, IGFs are being studied for their involvement in pathological conditions, including cancer progression, age-related muscle wasting (sarcopenia), neurodegenerative disorders, and diabetes. The therapeutic potential of recombinant IGF formulations, IGF receptor modulators, and analogs is expanding, especially as personalized medicine and biologics become more mainstream. The dual role of IGFs in promoting tissue regeneration and contributing to abnormal cell proliferation necessitates precise therapeutic targeting, creating opportunities for innovation in drug development, diagnostics, and targeted delivery systems.

How Is Innovation Shaping the Development of IGF-Based Therapies and Diagnostics?

Scientific advancements in molecular biology, protein engineering, and receptor signaling analysis have accelerated the development of IGF-based treatments. Recombinant IGF-1 therapies are currently being explored for conditions such as growth hormone insensitivity (Laron syndrome), severe burns, and muscle atrophy disorders. Biotech firms are actively designing IGF analogs with improved pharmacokinetics and receptor selectivity to maximize therapeutic benefits while minimizing off-target effects. In parallel, IGF-binding proteins (IGFBPs) are being leveraged to regulate bioavailability and enhance the safety profile of IGF-related drugs.

On the diagnostics front, the measurement of circulating IGF-1 levels has gained importance in assessing pituitary function, diagnosing growth disorders, and monitoring treatment efficacy in endocrine therapy. Additionally, IGF receptor expression profiling is emerging as a potential biomarker in oncology, particularly in breast, prostate, and colorectal cancers, where IGF signaling is implicated in tumor growth and resistance to therapy. Advances in bioassay platforms and high-throughput screening technologies are enabling more precise quantification of IGFs and their related pathways, expanding their role in clinical diagnostics and patient stratification.

Which Clinical and Research Domains Are Expanding the Demand for IGF-Based Solutions?

Endocrinology remains the primary domain for IGF utilization, especially in the treatment of pediatric growth disorders and GH deficiencies. However, the scope is broadening rapidly across other therapeutic areas. In musculoskeletal and orthopedic medicine, IGFs are being incorporated into tissue engineering and regenerative therapy protocols to enhance healing and repair of cartilage, tendons, and bone. Sports medicine is another growing application area, where IGF-based therapies are being studied for muscle regeneration and recovery in athletes, albeit amid regulatory and ethical scrutiny.

Oncology represents a significant frontier for IGF research, as several tumors exhibit overexpression of IGF receptors or reliance on IGF signaling for proliferation and survival. This has prompted the development of anti-IGF receptor antibodies and small-molecule inhibitors to disrupt these pathways in targeted cancer therapy. Neurology and geriatrics are emerging domains of interest, where IGFs are being investigated for their neuroprotective effects in Alzheimer's disease, cognitive decline, and age-related neurodegeneration. The broader application of IGFs in cell-based therapies, gene editing, and regenerative medicine underscores their strategic importance in future biomedical innovation.

The Growth in the Insulin-like Growth Factors Market Is Driven by Several Factors…

It is driven by the expanding understanding of IGF signaling in both health and disease, along with the rapid advancement of biopharmaceutical development platforms. The increasing prevalence of endocrine and metabolic disorders, coupled with aging populations worldwide, is fueling demand for therapies that address muscle wasting, growth deficiencies, and degenerative diseases. Technological breakthroughs in protein engineering and recombinant DNA technology are enabling the production of highly specific IGF analogs and modulators, improving therapeutic efficacy and safety.

In parallel, the integration of IGF assays in clinical diagnostics is becoming more common, particularly in growth hormone therapy monitoring, oncology biomarker profiling, and metabolic disease evaluation. The convergence of regenerative medicine and IGF-based interventions-supported by innovations in stem cell research and scaffold design-is opening new therapeutic avenues. Furthermore, expanding clinical research into the role of IGFs in aging, cognition, and immune modulation is positioning these molecules as key targets in next-generation biologic drug pipelines. The combination of cross-disciplinary applications, expanding clinical indications, and robust R&D investments is expected to sustain long-term growth in the insulin-like growth factors market.

SCOPE OF STUDY:

The report analyzes the Insulin-like Growth Factors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Mechano Growth Factor, Somatomedin C, IGF 1); End-Use (Hospitals, Medical Centers)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • ABL Bio
  • Biocon Limited
  • Biomed Industries, Inc.
  • Bio-Techne
  • Braasch Biotech LLC
  • Cell Guidance Systems
  • ConjuChem Biotechnologies Inc.
  • Eli Lilly and Company
  • HyTest Ltd.
  • Kriya Therapeutics
  • Novo Nordisk A/S
  • Oak Hill Bio
  • PerkinElmer (Revvity)
  • Repligen Corporation
  • Rivus Pharmaceuticals
  • Sana Biotechnology
  • STEMCELL Technologies
  • Thermo Fisher Scientific
  • Vertex Pharmaceuticals
  • Zymo Research

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Insulin-like Growth Factors - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Research Focus on IGFs as Therapeutic Targets in Cancer and Neurological Disorders Drives Market Growth
    • Expansion of Biopharmaceutical R&D Pipelines Spurs Interest in IGF-Based Drug Development
    • Increasing Use of IGF Pathway Modulation in Anti-Aging and Regenerative Medicine Expands Application Scope
    • Surge in Metabolic Disorder Prevalence Strengthens Business Case for IGF-Based Interventions
    • Technological Advances in Protein Engineering Enhance Stability and Efficacy of IGF Therapeutics
    • Collaborative Oncology Trials Highlight the Role of IGF-1 Inhibitors in Targeted Cancer Therapies
    • Rising Investment in Rare Disease Therapeutics Expands Niche Opportunities for IGF Modulators
    • Integration of Biomarkers for IGF Pathway Activation Enhances Precision in Patient Stratification
    • Growing Use of IGF-1 as a Diagnostic and Prognostic Biomarker Fuels Companion Diagnostic Development
    • Increased Focus on Musculoskeletal Recovery and Growth Disorders Drives Demand for IGF-1 Analogs
    • Expansion of Personalized Medicine Approaches Spurs Targeted Use of IGF Therapies in Subpopulations
    • Academic-Industry Collaborations in Endocrinology Research Strengthen Discovery Pipelines for IGF Pathway Drugs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Insulin-like Growth Factors Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Insulin-like Growth Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Insulin-like Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Mechano Growth Factor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Mechano Growth Factor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Mechano Growth Factor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Somatomedin C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Somatomedin C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Somatomedin C by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for IGF 1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for IGF 1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for IGF 1 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Medical Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Medical Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Medical Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • JAPAN
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • CHINA
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • EUROPE
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Insulin-like Growth Factors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Insulin-like Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • FRANCE
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • GERMANY
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Insulin-like Growth Factors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Insulin-like Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • INDIA
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Insulin-like Growth Factors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Insulin-like Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Insulin-like Growth Factors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Insulin-like Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030
  • AFRICA
    • Insulin-like Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Insulin-like Growth Factors by Type - Mechano Growth Factor, Somatomedin C and IGF 1 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Insulin-like Growth Factors by Type - Percentage Breakdown of Value Sales for Mechano Growth Factor, Somatomedin C and IGF 1 for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Insulin-like Growth Factors by End-Use - Hospitals and Medical Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Insulin-like Growth Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals and Medical Centers for the Years 2015, 2025 & 2030

IV. COMPETITION